There are two GLP-1 pills: Wegovy (semaglutide) was the first GLP-1 pill approved for weight loss in December 2025
Data availability The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information files
Collectively, these findings indicate that CH/BPC hydrogel possesses desirable physicochemical and antibacterial characteristics, highlighting their potential as multifunctional hydrogel for future biomedical applications
Homocysteine may be remethylated to regenerate methionine
The closest pipeline candidates are orforglipron, the first non-peptide oral GLP-1 from Eli Lilly, with an FDA decision anticipated in 2026, and retatrutide, a triple GLP-1/GIP/glucagon agonist in phase 3
3.3 Parkinsons disease PD is a neurodegenerative disorder that typically presents later in life with generalized bradykinesia and another symptom of resting tremor or rigidity